[Pharma clinics medication of the month. Esomeprazole].
Esomeprazole is the last PPI registered on the Belgian market. It is the stable s-isomer of omeprazole. It has a better pharmacokinetic profile than omeprazole (racemate), allowing also better clinical performances. Esomeprazole is the first PPI shown superior to omeprazole in acute and chronic treatment of gastro-esophageal reflux disease. Controlled trials with this drug have also allowed to define new cost-effective strategies, such as on demand treatment for endoscopy-negative gastro-esophageal reflux and one week treatment of Helicobacter pylori positive duodenal ulcer.
Louis
E
E
Service de Gastroentérologie, CHU de Liège.
D003363:Cost Control; D016527:Drug Costs; D004381:Duodenal Ulcer / Q000188:drug therapy / Q000382:microbiology; D004791:Enzyme Inhibitors / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D064098:Esomeprazole; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy; D006801:Humans; D009853:Omeprazole / Q000191:economics / Q000494:pharmacology* / Q000627:therapeutic use; D054328:Proton Pump Inhibitors
D004791:Enzyme Inhibitors; D054328:Proton Pump Inhibitors; D009853:Omeprazole; D064098:Esomeprazole